Neuraminidase inhibitors for the treatment and prevention of influenza

REFERENCES

• Textbook of influenza. Nicholson KG, Webster R, Hay A (Eds.), Blackwell Science Ltd. London, UK (1998):358–372.
   Google Scholar
• ENGLUND JA, CHAMPLIN RE, WYDE PR et al.: Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Chh. Infect. Dis. (1998) 26(6):1418–1424.
   PubMed Web of Science ®Google Scholar
• GRAMBAS S, BENNETT MS, HAY AJ: Influence of amantadine resistance mutations on the pH regulatory function of the M2 protein of influenza A viruses. Virology (1992) 191(2):541–549.
   PubMed Web of Science ®Google Scholar
• HOUCK P, HEMPHILL M, LACROIX S, HIRSH D, COX N: Amantadine-resistant influenza A in nursing homes. Identification of a resistant virus prior to drug use. Arch. Intern. Med. (1995) 155(5):533–537.
   Google Scholar
• ZIEGLER T, HEMPHILL ML, ZIEGLER ML et al.: Low incidence of rimantadine resistance in field isolates of influenza A viruses. J Infect. Dis. (1999) 180(4):935–939.
   PubMed Web of Science ®Google Scholar
• FRITZ RS, HAYDEN FG, CALFEE DP et al.: Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of iv. zanamivir treatment. j Infect. Dis. (1999) 180(3):586–593.
   PubMed Web of Science ®Google Scholar
• VON ITZSTEIN M, WU WY, KOK GB et al.: Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature (1993) 363(6428):418–423. ••First report of efficacy of zanamivir inanimals.
   Google Scholar
• COLMAN PM: Influenza virus neuraminidase: structure, antibodies and inhibitors. Protein Sci (1994) 3(10):1687–1696.
   PubMed Web of Science ®Google Scholar
• WOODS JM, BETHELL RC, COATES JA et al.: 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob. Agents Cheinother. (1993) 37(7):1473–1479. ••First report of antiviral activity ofzanamivir in vitro.
   Google Scholar
• KIM CU, LEW W, WILLIAMS MA et al:Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am. Chem. Soc. (1997) 119:681-690. First description of GS4071/oseltamivir.
   Google Scholar
• BABU YS, CHAND P, BANTIA S et al: BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally-active and selective influenza neuraminidase inhibitor through structure-based drug design. Med. Chem. (2000) 43(19):3482–3486. •Description of BCX-1812 design.
   Google Scholar
• BANTIA S, PARKER CD, ANANTH SL et al.: Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. (2001) 45(4):1162–1167. •BCX-1812 efficacy in vitro and in mice.
   Google Scholar
• SIDWELL RW, SMEE DE HUFFMAN JH etal.: In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201. Antimicrob. Agents Chemother. (2001) 45(3):749–757.
   Google Scholar
• SMEE DE HUFFMAN JH, MORRISON AC, BARNARD DL, SIDWELLRW: Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob. Agents Chemother. (2001) 45(3):743–748.
   PubMed Web of Science ®Google Scholar
• SIDWELL RW, SMEE DF, HUFFMAN JH etal.: Influence of virus strain, challenge dose and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201. Antiviral Res. (2001) 51(3):179–187.
   Google Scholar
• HAYDEN FG, TREANOR JJ, QU R, FOWLER CL: Safety and efficacy of an oral neuraminidase inhibitor RWJ-270201 in treating experimental influenza A in health adult volunteers. Ninth International Congress on Infectious Diseases. Buenos Aires, Argentina (2000). Abstract 80.018.
   Google Scholar
• DRUSANO GL, PRESTON SL, SMEE D et al.: Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing. Antimicrob. Agents Chemother. (2001) 45(7):2115–2118.
   PubMed Web of Science ®Google Scholar
• HAYDEN FG, OSTERHAUS AD, TREANOR JJ et al.: Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. GG167 Influenza Study Group. N Engl. J. Med. (1997) 337(13):874–880. ••Zanamivir treatment trials in the US andEurope.
   Google Scholar
• MAKELA MJ, PAUKSENS K, ROSTILA T et al.: Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomised, double-blind, placebo-controlled European study. I Infect. Dis. (2000) 40(1):42–48. •European zanamivir trials.
   Google Scholar
• BOIVIN G, GOYETTE N, HARDY I et al.: Rapid antiviral effect of inhaled zanamivir in the treatment of naturally-occurring influenza in otherwise healthy adults. J Infect. Dis. (2000) 181(4):1471–1474.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO K, OGAWA N, NEROME K et al.: Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group. Antiviral Ther (1999) 4(2):61–68. •Japanese zanamivir treatment trials.
   Google Scholar
• Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management Of Influenza In The Southern Hemisphere Trialists) Study Group. Lancet (1998) 352(9144):1877–1881. •Southern hemisphere zanamivir treatment trials.
   Google Scholar
• LALEZARI J, CAMPION K, KEENE 0,SILAGY C: Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomised controlled trials. Arch. Intern. Med. (2001) 161(2):212–217.
   PubMedGoogle Scholar
• KAISER L, KEENE ON, HAMMOND JM, ELLIOTT M, HAYDEN FG: Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch. Intern. Med. (2000) 160(21):3234–3240.
   PubMedGoogle Scholar
• MONTO AS, FLEMING DM, HENRY D etal.: Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. j Infect. Dis. (1999) 180(2):254–261.
   Google Scholar
• HEDRICK JA, BARZILAI A, BEHRE U et al.: Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomised controlled trial. Pediatr. Infect. Dis. j (2000) 19(5):410–417. •Zanamivir paediatric trials.
   Google Scholar
• Bronchospasm with zanamivir. Prescnre (2000) 9:80.
   Google Scholar
• CASS LM, GUNAWARDENA KA, •• MACMAHON MM, BYE A: Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir. Respit: Med. (2000) 94(2):166–173. •Safety of zanamivir in asthmatics.
   Google Scholar
• MURPHY KR, EIVINDSON APK, STEIN WJ et al.: Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease. Clin. Drug Invest. (2000) 20(5):337–345. ••Zanamivir effective and no adverse effectsin asthma or COPD patients.
   Google Scholar
• NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE: NICE issues guidance on zanamamivir (Relenza) for influenza. NICE(2000) 2000/047.
   Google Scholar
• NICHOLSON KG, AOKI FY, OSTERHAUS AD et al.: Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet (2000) 355(9218):1845–1850. ••Oseltamivir treatment trials.
   Google Scholar
• TREANOR JJ, HAYDEN FG, VROOMAN PS et al.: Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomised controlled trial. US Oral Neuraminidase Study Group. JAMA (2000) 283(8):1016–1024. ••US oseltamivir trials.
   Google Scholar
• HAYDEN FG, TREANOR JJ, FRITZ RS et al.: Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomised controlled trials for prevention and treatment. JAMA (1999) 282(13):1240–1246. ••Oseltamivir product information ontreatment, prophylaxis, side effects and resistance.
   Google Scholar
• HAYDEN FG, JENNINGS L, ROBSON R et al.: Oral oseltamivir in human experimental influenza B infection. Antiviral Ther. (2000) 5(3):205–213. •Oseltamivir influenza B trials.
   Google Scholar
• HE G, MASSARELLA J, WARD P: Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. (1999) 37(6):471–484.
   PubMed Web of Science ®Google Scholar
• WHITLEY RJ, HAYDEN FG, REISINGER KS et al.: Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. (2001) 20(2):127–133. •Paediatric trials of oseltamivir.
   Google Scholar
• LENEVA IA, GOLOUBEVA 0, FENTON RJ, TISDALE M, WEBSTER RG: Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob. Agents Chemother. (2001) 45(4):1216–1224.
   PubMed Web of Science ®Google Scholar
• LENEVA IA, ROBERTS N, GOVORKOVA EA, GOLOUBEVA OG, WEBSTER RG: The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res. (2000) 48(2):101–115.
   PubMed Web of Science ®Google Scholar
• REID AH, FANNING TG, JANCZEWSKI TA, TAUBENBERGER JK: Characterization of the 1918 'Spanish' influenza virus neuraminidase gene. Proc. Natl. Acad. Sci. USA (2000) 97(12):6785–6790.
   PubMed Web of Science ®Google Scholar
• MONTO AS, ROBINSON DE HERLOCHER ML et al.: Zanamivir in the prevention of influenza among healthy adults: a randomised controlled trial. JAMA (1999) 282(1):31–35. •Zanamivir prophylaxis study.
   Google Scholar
• KAISER L, HENRY D, FLACK NE KEENE 0, HAYDEN FG: Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. Clin. Infect. Dis. (2000) 30(3):587–589. •Zanamivir prophylaxis trials.
   Google Scholar
• HAYDEN FG, GUBAREVA LV, MONTO AS et al.: Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl. J. Med. (2000) 343(18):1282–1289. •Zanamivir family prophylaxis.
   Google Scholar
• LEE C, LOEB M, PHILLIPS A et a/.: Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. Infect. Control __krusp. Epidenhol. (2000) 21(11):700–704. •Zanamivir prophylaxis for amantadine resistant influenza.
   Google Scholar
• HAYDEN FG, ATMAR RL, SCHILLING M et al.: Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl. J. Med. (1999) 341(18):1336–1343.
   PubMed Web of Science ®Google Scholar
• WELLIVER R, MONTO AS, CAREWICZ 0 et al.: Effectiveness of oseltamivir in preventing influenza in household contacts: a randomised controlled trial. JAMA (2001) 285(6):748–754. •Oseltamivir post exposure prophylaxis.
   Google Scholar
• PARKER R, LOEWEN N, SKOWRONSKI D: Experience with oseltamivir in the control of a nursing home influenza B outbreak. Can. Commun. Dis. Rep. (2001) 27(5):37–40. •Oseltamivir prophylaxis in a nursing home.
   Google Scholar
• PETERS PHJ, GRAVENSTEIN S, NORWOOD P et al.: Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J. Am. Ceriatr. Soc. (2001) 49(8):1025–1031. •Oseltamivir prophylaxis in frail elderly.
   Google Scholar
• BURGER RA, BILLINGSLEY JL, HUFFMAN JH et al.: Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice. Immunopharmacology (2000) 47(1):45–52.
   PubMed Web of Science ®Google Scholar
• SID WELL RW, SMEE DF, BAILEY KW, BURGER RA: Primary immune system effects of the orally administered cyclopentane neuraminidase inhibitor RWJ-270201 in influenza virus-infected mice. Int. Immunopharmacol. (2001) 1(6):1211–1218.
   PubMed Web of Science ®Google Scholar
• COX RJ, MYKKELTVEDT E, SJURSEN H, HAAHEIM LR: The effect of zanamivir treatment on the early immune response to influenza vaccination. Vaccine (2001) 19(32)4743–4749.
   Google Scholar
• WEBSTER A, BOYCE M, EDMUNDSON S, MILLER I: Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers. Clin. Pharmacokinet. (1999) 36\(Suppl. 1):51–58. ••Zanamivir treatment has no effect on theimmune response to influenza vaccine.
   Google Scholar
• JOHNSON RJ, SCHWEINLE JE, BURROUGHS S: Zanamivir for the treatment of clinically diagnosed influenza in clinical practice. Clin. Dug Invest. (2000) 20 (5):327–336.
   Web of Science ®Google Scholar
• SILAGY C, WATTS R: Zanamivir, a new targeted therapy in the treatment of influenza. A patient perspective assessed by questionnaire. Clin. Drug Invest. (2000) 19(2):111–121.
   Web of Science ®Google Scholar
• DIGGORY P, FERNANDEZ C, HUMPHREY A, JONES V, MURPHY M: Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. Br. Med. J. (2001) 322(7286):577–579.
   PubMedGoogle Scholar
• HALL GH: Elderly people's technique in using dry powder inhalers. Zanamivir and unreason seem to go together. Br. Med. J. (2001) 323(7303):50.
   Google Scholar
• MCKIMM-BRESCHKIN JL: Resistance of influenza viruses to neuraminidase inhibitors - a review. Antiviral Res. (2000) 47(1):1–17. •Review of mechanisms of HA and NA resistance to the inhibitors.
   Google Scholar
• MCKIMM-BRESCHKIN JL, BUCK TJ, SAHASRABUDHE A et al.: Generation and characterization of variants of NWS/ G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob. Agents Chemother. (1996) 40(1):40–46.
   PubMed Web of Science ®Google Scholar
• TISDALE M: Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev Med. Viral. (2000) 10(1):45–55.
   PubMed Web of Science ®Google Scholar
• BUCK TJ, TIONG T, SAHASRABUDHE A et al.: Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. Virology (1995) 214(2):475–484.
   PubMed Web of Science ®Google Scholar
• GUBAREVA LV, ROBINSON MJ, BETHELL RC, WEBSTER RG: Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. Viral. (1997) 71(5):3385–3390. •Descriptions of R292K, E119 mutants in vitro.
   Google Scholar
• MCKIMM-BRESCHKIN JL, SAHASRABUDHE A, BUCK TJ et al: Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J. Viral. (1998) 72(3):2456–2462.
   PubMed Web of Science ®Google Scholar
• STASCHKE KA, HATCH SD, TANG JC et al: Inhibition of influenza virus haemagglutinin-mediated membrane fusion by a compound related to podocarpic acid. Virology (1998) 248(2):264–274.
   PubMed Web of Science ®Google Scholar
• VARGHESE JN, EPA VC, COLMAN PM: Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase. Protein Sci. (1995) 4(6):1081–1087.
   PubMed Web of Science ®Google Scholar
• STASCHKE KA, COLACINO JM, BAXTER AJ et al.: Molecular basis for the resistance of influenza viruses to 4-guanidino- Neu5Ac2en. Virology (1995) 214(2):642–646.
   PubMed Web of Science ®Google Scholar
• BARNETT JM, CADMAN A, BURRELL FM etal.: In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir. Virology (1999) 265(2):286–295.
   Google Scholar
• TAI CY, ESCARPE PA, SIDWELL RW et al.: Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob. Agents Chemother. (1998) 42(12):3234–3241.
   PubMed Web of Science ®Google Scholar
• CARR J, IVES J, ROBERTS N et al: Virological assessment in vitro and in vivo of an influenza H1N1 virus with a H274Y mutation in the neuraminidase gene. The 13th International Congress on Antiviral Research. Baltimore, Maryland, USA (16–21 April 2000). Antiviral Res. (2000) 46(1):A59. Abstract 79.
   Google Scholar
• WANG ZM, TAI CY, MENDEL DB: Characterization of an influenza A virus variant selected in vitro in the presence of the neuraminidase inhibitor, GS4071. The 13th International Congress on Antiviral Research, Baltimore, Maryland, USA (16–21 April 2000). Antiviral Res. (2000) 46(1):A60. Abstract 80.
   Google Scholar
• GUBAREVA LV, KAISER L, MATROSOVICH MN, SOO-HOO Y, HAYDEN FG: Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. (2001) 183(4):523–531. •H274Y oseltamivir mutant in H1N1 challenge.
   Google Scholar
• VARGHESE JN, SMITH PW, SOLLIS SL et al: Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure (1998) 6(6):735–746. •Structural differences in R292K NA binding oseltamivir and zanamivir.
   Google Scholar
• TAYLOR NR, CLEASBY A, SINGH 0 et al.: Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallo-graphic and molecular modelling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B. J. Med. Chem. (1998) 41(6):798–807.
   Google Scholar
• MCKIMM-BRESCHKIN JL, MCDONALD M, BLICK TJ, COLMAN PM: Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme. Virology (1996) 225(1):240–242.
   PubMed Web of Science ®Google Scholar
• BARNETT JM, CADMAN A, GOR D et al.: Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during Phase II clinical efficacy studies. Antimicrob. Agents Chemother. (2000) 44(1):78–87. ••No zanamivir resistance detected in PhaseII trials.
   Google Scholar
• GUBAREVA LV, MATROSOVICH MN, BRENNER MK, BETHELL RC, WEBSTER RG: Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. (1998) 178(5):1257–1262. •R152K mutant in immunocompromised zanamivir treated child.
   Google Scholar
• BURMEISTER WP RUIGROK RW, CUSACK S: The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO (1992) 11(1):49–56.
   Google Scholar
• IVES J, CARR J, ROBERTS N etal.: Anoseltamivir treatment-selected influenza A:N2 virus with a R292K mutation in the neuraminidase gene has reduced infectivity in vivo. J. Clin. Viral. (2000) 18:251–269.
   Google Scholar
• GUBAREVA L, TM CY, MENDEL DB et al.: Oseltamivir treatment of experimental influenza A/Texas/36/91 (H1N1) virus infection in humans: selection of a novel neuraminidase variant. The 13th International Congress on Antiviral Research. Baltimore, Maryland, USA (16–21 April 2000). Antiviral Res. (2000) 46(1):A59. Abstract 78.
   Google Scholar
• JACKSON HC, ROBERTS N, WANGE ZM, BELSHE R: Management of influenza. Use of new antivirals and resistance in perspective. Clin. Drug Invest. (2000) 20(6):447–454. ••Resistance data for oseltamivir.
   Google Scholar
• BANTIA S, ANANTH S, HORN L et al: Generation and characterization of a mutant of influenza A virus selected with neuraminidase inhibitor RWJ-270201. The 13th International Congress on Antiviral Research, Baltimore, Maryland USA (Apr 16–21, 2000). Antiviral Res. (2000) 46(1):A60. Abstract 82.
   Google Scholar
• SMEE DF, SID WELL RW, MORRISON AC et al: Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201. Antiviral Res. (2001) 52(3):251–259.
   PubMed Web of Science ®Google Scholar
• ZAMBON M, HAYDEN FG: Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res. (2001) 49(3):147–156.
   PubMed Web of Science ®Google Scholar
• CARROLL NV, DELAFUENTE JC, MCCLURE KL etal.: Economic burden of influenza-like illness in long-term-care facilities. Am. j Health Syst. Pharm. (2001) 58(12):1133–1138.
   Google Scholar
• SZUCS T: The socio-economic burden of influenza. j Antimicreb. Chemether. (1999) 44(Suppl. B):11–15.
   Google Scholar
• SZUCS TD: Influenza. The role of burden-of-illness research. Pharmarvecenemics (1999) 16\(Suppl. 1):27–32.
   Google Scholar
• MELTZER MI, COX NJ, FUKUDA K: The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg. Infect. Dis. (1999) 5(5):659–671.
   PubMed Web of Science ®Google Scholar
• MONTO AS, GRAVENSTEIN S, ELLIOTT M, COLOPY M, SCHWEINLE J: Clinical signs and symptoms predicting influenza infection. Arch. Intern. Med. (2000) 160(21):3243–3247. ••Good summary of influenza symptoms;cough and fever are predominant.
   Google Scholar